




Guest Editor



Kenneth Cusi, MD, FACP, FACE, is a professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at the University of Florida at Gainesville. He earned his medical degree in Buenos Aires, Argentina, and completed his endocrinology training as a fellow at Baylor College of Medicine in Houston, TX. After his fellowship, he joined the faculty of the Diabetes Division at the University of Texas Health Science Center in San Antonio, TX.

Dr. Cusi has published more than 250 peer-reviewed articles in the fields of obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD). His early work focused on the mechanisms causing type 2 diabetes and later on the interaction between type 2 diabetes and nonalcoholic steatohepatitis (NASH).

Dr. Cusi has been a long-time proponent of the view that NASH is a common complication of type 2 diabetes that deserves screening, as is done for retinopathy or nephropathy in people with type 2 diabetes. He has also advocated for the use of certain diabetes medications such as pioglitazone and glucagon-like peptide 1 receptor agonists more often and early in the course of treatment in this population to prevent cirrhosis. Both of these screening and treatment recommendations have been incorporated recently into NAFLD-related clinical practice guidelines from the American Diabetes Association and other medical organizations.

Diabetes Spectrum associate editor Jennifer M. Trujillo, PharmD, FCCP, BCPS, CDCES, BC-ADM, coordinated this From Research to Practice section.

<https://doi.org/10.2337/ds24-ge01>

©2024 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/journals/pages/license>.